Search for a command to run...
The bold mission of America's MEDITEX Companies is to bring an end to the burdens of disease, in all its forms.
Advancing healthcare through cutting-edge research and development, delivering breakthrough treatments that transform lives.
Sanveex is built by a team of experienced professionals with backgrounds across multinational and leading local pharmaceutical organizations. With strong expertise in product management, brand strategy, and market development, the team has deliberately planned and executed initiatives to build an organization focused on delivering meaningful and sustainable healthcare impact.
The leadership team brings combined experience from the pharmaceutical and MedTech sectors, positioning Sanveex to address complex healthcare challenges through solutions that are both innovative and practical. Within a relatively short period, Sanveex has established a growing healthcare product portfolio designed to improve patient outcomes and strengthen healthcare delivery across Bangladesh.
Bringing cutting-edge medical technologies from around the world to enhance healthcare solutions and patient outcomes.
Ensuring the highest standards in every product and service we provide, prioritizing patient safety and satisfaction.
Committed to advancing medical care through innovative solutions that empower healthcare professionals and improve patient lives.
Tailoring medical products and solutions to meet the specific needs of healthcare providers and institutions.
Adhering strictly to international medical standards and regulations to ensure safety, reliability, and trust.
Building strong, long-term partnerships with hospitals, clinics, and distributors to drive sustainable healthcare growth.
”When I began looking for the 'best' center for Max I chose Medicol. You are the best. Many thanks to you and your warm, concerned staff...”
Explore the latest updates, medical breakthroughs, and announcements from our team of specialists.
<p>Sanveex leadership will provide a comprehensive overview of the company's growth strategy and oncology pipeline at the upcoming JP Morgan conference.</p>
The acquisition marks a significant step in expanding our therapeutic reach and bringing innovative treatments to patients with rare diseases.
Latest phase II results demonstrate exceptional safety and efficacy profiles for our lead candidate in metabolic disorders.